Concetta Barone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Concetta Barone has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Corrado Romano
Section of Clinical Biochemistry and MedicalGenetics, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy, Italy
31 shared publications - Michele Salemi
Oasi Research Institute-IRCCS, 94018 Troina, Italy
14 shared publications Carmelo Romano
A IRCCS Associazione Oasi Institute for Research on Mental Retardation and Brain Aging , Troina , Italy
13 shared publications- Maria Grazia Salluzzo
Oasi Research Institute-IRCCS, 94018 Troina, Italy
13 shared publications Paolo Bosco
IRCCS Associazione Oasi Maria SS, Institute for Research on Mental Retardation and Brain Aging, Troina, Italy
11 shared publications- Cataldo Scavuzzo
Oasi Institute for Research on Mental Retardation and Brain Aging
8 shared publications
Latest Publications
- 28 June 2021
- Published by Springer Nature in Molecular Biology Reports
- Vol. 48 (6) , 5335-5338
CCR3 gene overexpression in patients with Down syndrome
Chromosome 21 trisomy or Down syndrome (DS) is the most common genetic cause of intellectual disability (ID). DS is also associated with hypotonia, muscle weakness, autoimmune diseases, and congenital heart disease. C–C chemokine receptor type 3 (CCR3) plays a role in inflammatory, autoimmune, and neuronal migration mechanisms. The present study aimed to evaluate the expression of the CCR3 gene by NGS and qRT-PCR in patients with DS and normal controls (NC). The CCR3 gene was over-expressed in DS patients compared to NC. These data suggest that an over-expression of the CCR3 gene is associated with the phenotype of patients with DS.
- 28 June 2021
- Published by Springer Nature in Molecular Biology Reports
- Vol. 48 (6) , 5335-5338
CCR3 gene overexpression in patients with Down syndrome
Chromosome 21 trisomy or Down syndrome (DS) is the most common genetic cause of intellectual disability (ID). DS is also associated with hypotonia, muscle weakness, autoimmune diseases, and congenital heart disease. C–C chemokine receptor type 3 (CCR3) plays a role in inflammatory, autoimmune, and neuronal migration mechanisms. The present study aimed to evaluate the expression of the CCR3 gene by NGS and qRT-PCR in patients with DS and normal controls (NC). The CCR3 gene was over-expressed in DS patients compared to NC. These data suggest that an over-expression of the CCR3 gene is associated with the phenotype of patients with DS.
- 1 December 2017
- Published by Elsevier in European Journal of Pharmacology
- Vol. 817, 7-19
Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome
- 1 December 2017
- Published by Elsevier in European Journal of Pharmacology
- Vol. 817, 7-19
Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome
- 7 December 2016
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 30 (22) , 2752-2754
A polymorphism (rs1042522) in TP53 gene is a risk factor for Down Syndrome in Sicilian mothers
Objective: Trisomy 21 is the most frequent genetic cause of intellectual disability. Tumor Protein 53 (TP53) gene down-regulation triggers chromosomal instability. A TP53 gene polymorphism c.215G > C (rs1042522) is associated with accumulation of aneuploid cells. We analyzed the TP53 c.215G > C (rs1042522) polymorphism in Sicilian mothers of subjects with Down Syndrome (DS) within a case-control study. Methods: Nucleotide polymorphism was detected by pyrosequencing technology. Results: The distribution of TP53 c.215G > C polymorphism showed significant difference between mothers of subjects with DS and controls. Conclusions: Our data show that TP53 c.215G > C polymorphism is a risk factor for DS in Sicilian mothers.
- 7 December 2016
- Published by Taylor & Francis in The Journal of Maternal-Fetal & Neonatal Medicine
- Vol. 30 (22) , 2752-2754
A polymorphism (rs1042522) in TP53 gene is a risk factor for Down Syndrome in Sicilian mothers
Objective: Trisomy 21 is the most frequent genetic cause of intellectual disability. Tumor Protein 53 (TP53) gene down-regulation triggers chromosomal instability. A TP53 gene polymorphism c.215G > C (rs1042522) is associated with accumulation of aneuploid cells. We analyzed the TP53 c.215G > C (rs1042522) polymorphism in Sicilian mothers of subjects with Down Syndrome (DS) within a case-control study. Methods: Nucleotide polymorphism was detected by pyrosequencing technology. Results: The distribution of TP53 c.215G > C polymorphism showed significant difference between mothers of subjects with DS and controls. Conclusions: Our data show that TP53 c.215G > C polymorphism is a risk factor for DS in Sicilian mothers.
- 1 November 2016
- Published by Wolters Kluwer Health in Menopause
- Vol. 23 (11) , 1247-1251
Low AMH levels as a marker of reduced ovarian reserve in young women affected by Down's syndrome
Objective: Women with Down's syndrome (DS) experience menopause earlier than healthy women and are twice as likely to undergo premature ovarian insufficiency. Menopause accelerates cognitive decline and is associated with a twofold increased mortality risk in DS women. Nonetheless, no previous studies investigated the ovarian reserve in this population. The aim of the present study was to evaluate the circulating antimullerian hormone (AMH) levels in DS women with regular menstrual cycles, in comparison with those observed in an age-matched group of healthy women. Methods: Fourteen women with DS and 20 normo-ovulatory volunteers were enrolled in this study. A general physical examination was performed. Hormonal assays, including AMH, fasting insulin levels, and homeostatic model assessment-insulin resistance, were investigated in all participants. Results: AMH levels were significantly lower in DS women compared with controls (1.34 ± 1.11 vs 3.01 ± 1.65 ng/mL, P < 0.01). Prolactin concentrations were in the normal range, although higher in DS women compared with controls (P < 0.01). After dividing the participants according to age, AMH was significantly lower in the DS group compared with controls, both below and above 30 years of age (1.77 vs 3.73 ng/mL, P < 0.01; 0.28 vs 2.20 ng/mL, P < 0.01, respectively). AMH was inversely correlated with age in both groups, and directly correlated with testosterone and dehydroepiandrosterone sulfate only in DS women. In the same participants, AMH showed a tendency toward a direct correlation with insulin levels (P = 0.055). Conclusions: AMH levels were significantly lower in DS women compared with age-matched controls. A subanalysis of data in DS participants under 30 years of age suggested an early follicular depletion related to trisomy 21.
- 1 November 2016
- Published by Wolters Kluwer Health in Menopause
- Vol. 23 (11) , 1247-1251
Low AMH levels as a marker of reduced ovarian reserve in young women affected by Down's syndrome
Objective: Women with Down's syndrome (DS) experience menopause earlier than healthy women and are twice as likely to undergo premature ovarian insufficiency. Menopause accelerates cognitive decline and is associated with a twofold increased mortality risk in DS women. Nonetheless, no previous studies investigated the ovarian reserve in this population. The aim of the present study was to evaluate the circulating antimullerian hormone (AMH) levels in DS women with regular menstrual cycles, in comparison with those observed in an age-matched group of healthy women. Methods: Fourteen women with DS and 20 normo-ovulatory volunteers were enrolled in this study. A general physical examination was performed. Hormonal assays, including AMH, fasting insulin levels, and homeostatic model assessment-insulin resistance, were investigated in all participants. Results: AMH levels were significantly lower in DS women compared with controls (1.34 ± 1.11 vs 3.01 ± 1.65 ng/mL, P < 0.01). Prolactin concentrations were in the normal range, although higher in DS women compared with controls (P < 0.01). After dividing the participants according to age, AMH was significantly lower in the DS group compared with controls, both below and above 30 years of age (1.77 vs 3.73 ng/mL, P < 0.01; 0.28 vs 2.20 ng/mL, P < 0.01, respectively). AMH was inversely correlated with age in both groups, and directly correlated with testosterone and dehydroepiandrosterone sulfate only in DS women. In the same participants, AMH showed a tendency toward a direct correlation with insulin levels (P = 0.055). Conclusions: AMH levels were significantly lower in DS women compared with age-matched controls. A subanalysis of data in DS participants under 30 years of age suggested an early follicular depletion related to trisomy 21.
- 21 July 2016
- Published by Wiley in Alzheimer's & Dementia
- Vol. 12 (11) , 1132-1148
An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation
Introduction: Given that Alzheimer's pathology develops silently over decades in Down syndrome (DS), prognostic biomarkers of dementia are a major need.Methods: We investigated the plasma levels of Aβ, proNGF, tPA, neuroserpin, metallo‐proteases and inflammatory molecules in 31 individuals with DS (with and without dementia) and in 31 healthy controls. We examined associations between biomarkers and cognitive decline.Results: Aβ40 and Aβ42 were elevated in DS plasma compared to controls, even in DS individuals without dementia. Plasma Aβ correlated with the rate of cognitive decline across 2 years. ProNGF, MMP‐1, MMP‐3, MMP‐9 activity, TNF‐α, IL‐6, and IL‐10 were higher in DS plasma, even at AD‐asymptomatic stages. Declining plasma Aβ42 and increasing proNGF levels correlated with cognitive decline. A combined measure of Aβ and inflammatory molecules was a strong predictor of prospective cognitive deterioration.Conclusions: Our findings support the combination of plasma and cognitive assessments for the identification of DS individuals at risk of dementia.
- 21 July 2016
- Published by Wiley in Alzheimer's & Dementia
- Vol. 12 (11) , 1132-1148
An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation
Introduction: Given that Alzheimer's pathology develops silently over decades in Down syndrome (DS), prognostic biomarkers of dementia are a major need.Methods: We investigated the plasma levels of Aβ, proNGF, tPA, neuroserpin, metallo‐proteases and inflammatory molecules in 31 individuals with DS (with and without dementia) and in 31 healthy controls. We examined associations between biomarkers and cognitive decline.Results: Aβ40 and Aβ42 were elevated in DS plasma compared to controls, even in DS individuals without dementia. Plasma Aβ correlated with the rate of cognitive decline across 2 years. ProNGF, MMP‐1, MMP‐3, MMP‐9 activity, TNF‐α, IL‐6, and IL‐10 were higher in DS plasma, even at AD‐asymptomatic stages. Declining plasma Aβ42 and increasing proNGF levels correlated with cognitive decline. A combined measure of Aβ and inflammatory molecules was a strong predictor of prospective cognitive deterioration.Conclusions: Our findings support the combination of plasma and cognitive assessments for the identification of DS individuals at risk of dementia.
- 31 March 2016
- Published by Springer Nature in Neurological Sciences
- Vol. 37 (5) , 793-795
Killer-specific secretory (Ksp37) gene expression in subjects with Down’s syndrome
- 31 March 2016
- Published by Springer Nature in Neurological Sciences
- Vol. 37 (5) , 793-795
Killer-specific secretory (Ksp37) gene expression in subjects with Down’s syndrome
- 26 August 2015
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 24 (5) , 652-659
The Koolen-de Vries syndrome: a phenotypic comparison of patients with a 17q21.31 microdeletion versus a KANSL1 sequence variant
The Koolen-de Vries syndrome (KdVS; OMIM #610443), also known as the 17q21.31 microdeletion syndrome, is a clinically heterogeneous disorder characterised by (neonatal) hypotonia, developmental delay, moderate intellectual disability, and characteristic facial dysmorphism. Expressive language development is particularly impaired compared with receptive language or motor skills. Other frequently reported features include social and friendly behaviour, epilepsy, musculoskeletal anomalies, congenital heart defects, urogenital malformations, and ectodermal anomalies. The syndrome is caused by a truncating variant in the KAT8 regulatory NSL complex unit 1 (KANSL1) gene or by a 17q21.31 microdeletion encompassing KANSL1. Herein we describe a novel cohort of 45 individuals with KdVS of whom 33 have a 17q21.31 microdeletion and 12 a single-nucleotide variant (SNV) in KANSL1 (19 males, 26 females; age range 7 months to 50 years). We provide guidance about the potential pitfalls in the laboratory testing and emphasise the challenges of KANSL1 variant calling and DNA copy number analysis in the complex 17q21.31 region. Moreover, we present detailed phenotypic information, including neuropsychological features, that contribute to the broad phenotypic spectrum of the syndrome. Comparison of the phenotype of both the microdeletion and SNV patients does not show differences of clinical importance, stressing that haploinsufficiency of KANSL1 is sufficient to cause the full KdVS phenotype.
- 26 August 2015
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 24 (5) , 652-659
The Koolen-de Vries syndrome: a phenotypic comparison of patients with a 17q21.31 microdeletion versus a KANSL1 sequence variant
The Koolen-de Vries syndrome (KdVS; OMIM #610443), also known as the 17q21.31 microdeletion syndrome, is a clinically heterogeneous disorder characterised by (neonatal) hypotonia, developmental delay, moderate intellectual disability, and characteristic facial dysmorphism. Expressive language development is particularly impaired compared with receptive language or motor skills. Other frequently reported features include social and friendly behaviour, epilepsy, musculoskeletal anomalies, congenital heart defects, urogenital malformations, and ectodermal anomalies. The syndrome is caused by a truncating variant in the KAT8 regulatory NSL complex unit 1 (KANSL1) gene or by a 17q21.31 microdeletion encompassing KANSL1. Herein we describe a novel cohort of 45 individuals with KdVS of whom 33 have a 17q21.31 microdeletion and 12 a single-nucleotide variant (SNV) in KANSL1 (19 males, 26 females; age range 7 months to 50 years). We provide guidance about the potential pitfalls in the laboratory testing and emphasise the challenges of KANSL1 variant calling and DNA copy number analysis in the complex 17q21.31 region. Moreover, we present detailed phenotypic information, including neuropsychological features, that contribute to the broad phenotypic spectrum of the syndrome. Comparison of the phenotype of both the microdeletion and SNV patients does not show differences of clinical importance, stressing that haploinsufficiency of KANSL1 is sufficient to cause the full KdVS phenotype.
- 2 June 2015
- Vol. 61 (3) , 6-7
Letter to Editor: Cytochrome b gene expression in down syndrome subjects.
- 2 June 2015
- Vol. 61 (3) , 6-7
Letter to Editor: Cytochrome b gene expression in down syndrome subjects.
- Open Access
- 11 March 2015
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 10 (1)
LDOC1 expression in fibroblasts of patients with Down syndrome
Down syndrome (DS) is characterised by intellectual disability and is caused by trisomy 21. Apoptosis is a programmed cell death process and is involved in neurodegenerative diseases such as Alzheimer. People with DS can develop some traits of Alzheimer disease at an earlier age than subjects without trisomy 21. The leucine zipper, down regulated in cancer 1 (LDOC1) appears to be involved in the apoptotic pathways. The aim of the present work was to detect the presence of intracellular synthesis of LDOC1 protein and LDOC1 mRNA in fibroblast cultures from DS subjects. The western blot shows the presence of LDOC1 protein in fibroblasts of DS subjects but no evidence of LDOC1 protein in fibroblasts of normal subjects. LDOC1 gene mRNA expression is increased in fibroblasts from DS subjects compared to fibroblasts from normal subjects. The data obtained from this study strengthen the hypothesis that the over-expression of LDOC1 gene could play a role in determining the phenotype of individuals with DS but does not exclude that this results from apoptotic mechanisms
- 11 March 2015
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 10 (1)
Open AccessLDOC1 expression in fibroblasts of patients with Down syndrome
Down syndrome (DS) is characterised by intellectual disability and is caused by trisomy 21. Apoptosis is a programmed cell death process and is involved in neurodegenerative diseases such as Alzheimer. People with DS can develop some traits of Alzheimer disease at an earlier age than subjects without trisomy 21. The leucine zipper, down regulated in cancer 1 (LDOC1) appears to be involved in the apoptotic pathways. The aim of the present work was to detect the presence of intracellular synthesis of LDOC1 protein and LDOC1 mRNA in fibroblast cultures from DS subjects. The western blot shows the presence of LDOC1 protein in fibroblasts of DS subjects but no evidence of LDOC1 protein in fibroblasts of normal subjects. LDOC1 gene mRNA expression is increased in fibroblasts from DS subjects compared to fibroblasts from normal subjects. The data obtained from this study strengthen the hypothesis that the over-expression of LDOC1 gene could play a role in determining the phenotype of individuals with DS but does not exclude that this results from apoptotic mechanisms
- 16 October 2014
- Published by Springer Nature in Neurological Sciences
- Vol. 36 (6) , 1065-1066
NF-kB1 gene expression in Down syndrome patients
- 16 October 2014
- Published by Springer Nature in Neurological Sciences
- Vol. 36 (6) , 1065-1066
NF-kB1 gene expression in Down syndrome patients